Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice
AIMS OF THE STUDY Atezolizumab is an approved therapy for urothelial carcinoma based on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study evaluated atezolizumab in a broader patient population more representative of real-world populations. Among a...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2020-05-01
|
| Col·lecció: | Swiss Medical Weekly |
| Matèries: | |
| Accés en línia: | https://www.smw.ch/index.php/smw/article/view/2791 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|